FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to α-interferon aqueous solution for injections. An aqueous solution has from 0.1 x 106 to 100 x 106 IU/ml of α-interferon, buffer system maintaining pH value of solution in the range from 4.5 to 7.1, chelating agent, derivative of poly-(hydroxy-1,2-ethane-diyl)-sorbitan mono-9-octadecanoate taken in the amount that is necessary for stabilization of α-interferon and prevention of its inactivation, agent providing osmosis of solution, preserving agent showing antibacterial activity and water for injection. EFFECT: high physical and chemical stability, high biological activity. 8 cl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN INTERFERON-ALPHA-TWO AQUEOUS SOLUTION FOR INJECTION | 2002 |
|
RU2238758C2 |
| COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
| ALPHA-INTERFERON PREPARATION IN THE FORM OF STABLE AQUEOUS SOLUTION FOR INJECTIONS | 2004 |
|
RU2255729C1 |
| POWDER ANTIBACTERIAL COMPOSITION CONTAINING HYDRATED CEFTIBUTEN FOR ORAL USING AS A SUSPENSION | 1993 |
|
RU2123863C1 |
| SOLUTION FOR INJECTION, RECOMBINANT PLASMID DNA pSX50 ENCODING SYNTHESIS OF HUMAN RECOMBINANT ALPHA-2b INTERFERON, STRAIN Escherichia coli SX50 AS INDUSTRIAL STRAIN-PRODUCER OF HUMAN RECOMBINANT ALPHA-2b INTERFERON AND METHOD FOR INDUSTRIAL PREPARING INTERFERON ALPHA-2b | 2006 |
|
RU2319502C1 |
| CONTACT LENS CARE SOLUTION | 2020 |
|
RU2755298C1 |
| PHARMACEUTICAL COMPOSITIONS OF ERYTHROPOIETIN | 2000 |
|
RU2225221C2 |
| ALPHA-INTERFERON COMPOSITION AS AQUEOUS SOLUTION | 2000 |
|
RU2232595C2 |
| ANTIFUNGAL COMPOSITE WITH ENHANCED BIOAVAILABILITY | 1997 |
|
RU2207119C2 |
| INTERFERON AN AQUEOUS SOLUTION | 1996 |
|
RU2113845C1 |
